Ken Griffin Aclaris Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $24,543 - $33,048	-24,300 Reduced 64.8%	13,200 $14,000
Q1 2024 May 15, 2024	BUY	$0.92 - $1.44 $18,584 - $29,088	20,200 Added 116.76%	37,500 $46,000
Q4 2023 Feb 14, 2024	SELL	$0.64 - $6.49 $133,120 - $1.35 Million	-208,000 Reduced 92.32%	17,300 $18,000
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $770,800 - $1.29 Million	117,500 Added 109.0%	225,300 $1.54 Million
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $74,955 - $101,080	-9,500 Reduced 8.1%	107,800 $1.12 Million
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $770,630 - $1.96 Million	109,000 Added 1313.25%	117,300 $948,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $118,939 - $152,471	8,300 New	8,300 $130,000

52.4M

32.4K

3.3K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $139M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.